Opinion for the Court filed by Circuit Judge GINSBURG.
Opinion concurring in the result filed by Circuit Judge GARLAND.
GINSBURG, Circuit Judge:Pursuant to the Freedom of Information Act, the Public Citizen Health Research Group asked the Food and Drug Administration for documents relating to drug applications that had been abandoned for health or safety reasons. The FDA denied this request and Public Citizen sued the agency in district court, where Schering Corporation, which had submitted five in-vestigational new drug applications (INDs) of the sort requested by Public Citizen, intervened as a defendant. The FDA and Schering claimed that certain of the documents in those five INDs contained confidential commercial information and therefore could be withheld under Exemption 4 of the FOIA, 5 U.S.C. § 552(b)(4). Public Citizen argued that the documents could not be withheld under that exemption and that in any event disclosure was required under 21 U.S.C. § 355(l), which it asserted sets a standard for nondisclosure higher than that in Exemption 4 of the FOIA.
The district court ordered the release of all the disputed documents on the ground that, although some could be withheld under Exemption 4, the FDA had not met the higher standard of § 355(l). We affirm the judgment of the district court in part, albeit on a different ground, reverse it in part, and remand the case for further proceedings consistent with this opinion.
*901I. Background
Before marketing a new drug in the United States a manufacturer must obtain the approval of the FDA contingent upon clinical (¿a, human) tests showing that the drug is safe and effective. See 21 U.S.C. § 355(a), (d). Before a company may begin clinical testing, however, it must first submit an IND describing the drug, the results of laboratory and pre-clinical (ie., animal) testing, and the proposed clinical testing. See id. § 355(i). An applicant may begin the proposed clinical testing 30 days after submitting its IND; the FDA, however, may place the testing on hold at any time. See 21 C.F.R. §§ 312.40(b), 312.42. During clinical testing the company must update its IND with safety reports, annual reports on the progress of the testing, any amendments to the testing protocols, and other information. See id. §§ 312.30-312.33. After clinical testing, the company must file a new drug application (NDA), which must include information about the results of both pre-clinical and clinical testing; information previously submitted in the IND may be incorporated by reference into the NDA. See 21 U.S.C. § 355(b); 21 C.F.R. § 314.50.
This case began when Public Citizen filed a. FOIA request, with the FDA for “[a]ll documents concerning pre-clinical and clinical studies for all prescription drugs which had a discontinuance of the clinical trials because of death or serious injury of patients or because of safety concerns from preclinical studies ... between January ■ 1, 1990 and [July 12, 1993].” When the agency denied the request Public Citizen filed suit in. the district court seeking release of the documents.
The FDA moved to dismiss, arguing that although a search of its database identified 230 INDs for which the agency had received safety reports and which were either withdrawn, terminated, or placed on hold by the FDA, it could not without an unduly burdensome manual search of each file determine which of these were discontinued “because of’ health or safety concerns. The district court denied the motion to dismiss, and the agency then determined that 14 of the 230 INDs were responsive to the FOIA request; of those, only portions of the five filed by Sehering are at issue in this appeal.
On cross-motions for summary judgment, the district court first held that the disputed documents in the five INDs could be withheld under Exemption 4, because they contain “commercial or financial information obtained from a person [that is] privileged or confidential.” 5 U.S.C. § 552(b)(4). Schering’s affidavits demonstrated to the court that disclosure would “cause substantial harm to [its] competitive position.” National Parks & Conservation Ass’n v. Morton (“National Parks I”), 498 F.2d 765, 770 (D.C.Cir.1974). The district court then held that under 21 U.S.C. § 355(l)(1) the FDA must nonetheless disclose the same documents absent “extraordinary circumstances.” Finding no such circumstances here, the court granted summary judgment for Public Citizen and ordered the agency to release the disputed documents. Both the FDA and Sehering appealed to this court.
II. Analysis
The FDA and Sehering argue that the agency may under § 355(l) withhold any data pertaining to the safety and effectiveness of an abandoned drug that it may withhold under Exemption 4 of the FOIA — in other words, that the standards in the two statutes are the same. Public Citizen contends that § 355(l) imposes a more stringent standard for nondisclosure than that in Exemption 4. We need not resolve this dispute over the relationship between the two statutes, however, because we hold that § 355(2) does not apply to INDs. Viewing the documents solely through the lens of Exemption 4, we conclude that the FDA has justified withholding at least some information in four of the five INDs.
*902A. Section 355(l)
Section 355(l) requires the FDA, upon request, to disclose "[s]afety and effectiveness data and information which has been submitted in an application under subsection (b) [of § 355] for a drug" that subsequently was abandoned by its sponsor, "unless extraordinary circumstances are shown." 21 U.S.C. § 355(1)(1). No one disputes that an "application under subsection (b)" is an NDA. Schering argues that § 355(l), therefore, simply does not apply to information in an IND, which is submitted under subsection (i), not subsection (b). That is indeed the plain meaning of the provision, and we cannot understand how "submitted in an application under subsection (b)" could include anything other than information submitted in an NDA. Public Citizen's arguments to the contrary are not convincing.
First, Public Citizen contends that the agency applies § 355(l) to the disclosure of material submitted in an IND and that we should accord "substantial weight" to the FDA's view of its regulatory structure. As Schering notes, however, the FDA has never promulgated a regulation-nor are we apprised of any FDA decision or other document-so interpreting § 355(l). More important, it is apparent that the Congress has spoken to "the precise question at issue" here, Chevron U.S.A. Inc. v. NRDC, 467 U.S. 837, 842-43 & n. 9, 104 S.Ct. 2778, 81 L.Ed.2d 694 (1984): § 355(l) by its terms applies only to "safety and effectiveness data and information" submitted in an NDA. Therefore, even if the agency had interpreted the phrase "subsection (b)" in § 355 to include information submitted in an IND, we could not defer to that interpretation.
Second, Public Citizen argues that to read § 355(l) as applying only to NDAs is erroneous because "the IND and NDA are not two distinct stages" in the drug approval process. In support of this view, Public Citizen points out that the FDA stores information related to the approval of a drug in its IND file even after an NDA is submitted. The fact remains, however, that NDAs and INDs are the subject of ~eparate subsections of § 355 and the Congress referred only to one of them in § 355(l). We cannot help but conclude, therefore, that the statute treats the submission of an NDA as a discrete event in the drug approval process, regardless how the FDA maintains its files.
Third, Public Citizen contends that a plain meaning approach to § 355(l) leads to an illogical result: data and information submitted in an IND which later, rather than being resubmitted in an NDA, are incorporated by reference into the NDA would not be "submitted in an application under subsection (b)," that is, an NDA. The FDA and Schering offer a more sensible view, however: to incorporate IND materials by reference into an NDA is indeed to submit those materials as part of the NDA. By the same token, once those materials are incorporated by reference into an NDA, their disclosure is subject to the standard in § 355(l) even if the FDA keeps them in an IND file.
Finally, Public Citizen argues that "[ut makes no sense to assume Congress enacted a statute mandating disclosure of safety and effectiveness data only when the sponsor had filed an NDA .., but not when the sponsor had abandoned the drug earlier in the process." In this regard Public Citizen points out that the FDA accords the same treatment to such data regardless whether they were submitted in an NDA or an IND. Specifically, the FDA by regulation (21 C.F.R. § 312.130(b)) provides that disclosure of information in an IND "will be handled in accordance with" the regulation governing disclosure of information in an NDA (21 C.F.R. § 314.430(f)).
Nonetheless, when the Congress enacted § 355(l) it did not mandate disclosure of information in an IND. Moreover, Scher-ing offers a perfectly sensible explanation why the Congress did not do so. The Drug Price Competition and Patent Term Restoration Act of 1984, Pub.L. No. 98-417, 98 Stat. 1585, of which § 355(l) was a part, established an abbreviated process *903through which a company could obtain approval to market the generic equivalent of a drug that the FDA had previously approved on the basis of an NDA. See Mova Pharm. Corp. v. Shalala, 140 F.3d 1060, 1063-65 (D.C.Cir.1998) (describing abbreviated new drug application process). The statute, Schering continues, does “not deal with INDs at all, and Congress had no reason in this legislative context to extend [§ 355(l)] to them.” Even if, as Public Citizen contends, it would be more wise not to treat information submitted in an IND differently from information submitted in an NDA, a matter about which we express no opinion, the Congress may, of course, approach matters one step at a time. See FCC v. Beach Communications, Inc., 508 U.S. 307, 316, 113 S.Ct. 2096, 124 L.Ed.2d 211 (1993)
In view of the above analysis, we hold that § 355(1) does not apply to data and information submitted solely in an IND; such information may be withheld if the agency carries its burden under Exemption 4 of the FOIA. Schering did not file an NDA for four of the five INDs at issue in this case (which four we consider in Part II.B.l), but concedes that it filed two NDAs relating to the drug at issue in IND No. 18113. We need not determine the import of Schering’s concession, however, for we conclude (in Part II.B.2) that documents in that IND cannot be withheld under the allegedly more lenient standard in Exemption 4.
B. Exemption 4
Exemption 4 of the FOIA permits an agency to withhold “commercial or financial information [that was] obtained from a person [and is] privileged or confidential.” 5 U.S.C. § 552(b)(4). Information that a person is required to submit to the Government is considered confidential only if its disclosure is likely either “(1) to impair the Government’s ability to obtain necessary information in the future; or (2) to cause substantial harm to the competitive position of the person from whom' the information was obtained.” National Parks I, 498 F.2d at 770. In the present case the FDA and Schering invoke only the latter standard. Meanwhile, Public Citizen claims disclosure would prevent other drug companies “from' repeating Schering’s mistakes, thereby avoiding risk to human health,” and relies upon dicta in several district court opinions in arguing that under Exemption 4 the court should gauge whether the competitive harm done to the sponsor of an IND by the public disclosure of confidential information “is outweighed by the strong public interest in safeguarding the health of human trial participants.”* See Public Citizen Health *904Research Group v. FDA, 964 F.Supp. 413, 415 (D.D.C.1997); see also Teich v. FDA 751 F.Supp. 243, 253 (D.D.C.1990); AT&T Information Systems, Inc. v. General Servs. Admin., 627 F.Supp. 1396, 1403 (D.D.C.1986).
We reject Public Citizen’s proposal because a consequentialist approach to the public interest in disclosure is inconsistent with the “[b]alanc[e of] private and public interests” the Congress struck in Exemption 4. Critical Mass Energy Project v. NRC, 975 F.2d 871, 872 (D.C.Cir.1992) (in banc); see also FBI v. Abramson, 456 U.S. 615, 621, 102 S.Ct. 2054, 72 L.Ed.2d 376 (1982) (although FOIA implements policy of broad disclosure, the Congress also realized “that legitimate governmental and private interests could be harmed by release of certain types of information and provided nine specific exemptions under which disclosure could be refused”); see also National Parks I, 498 F.2d at 770 (legislative history of FOIA “firmly supports the inference that [Exemption 4] is intended for the benefit of persons who supply information”). That balance is accurately reflected in the test of confidentiality set forth in National Parks I, which was “known to and acquiesced in by Congress” when it enacted 5 U.S.C. § 552b(c)(4), an exemption to the Government in the Sunshine Act that is identical to Exemption 4 of the FOIA. CNA Fin. Corp. v. Donovan, 830 F.2d 1132, 1153 n. 146 (D.C.Cir.1987) (describing legislative history of § 552b(e)(4)).
In other words, the Congress has already determined the relevant public interest: if through disclosure “the public would learn something directly about the workings of the Government,” then the information should be disclosed unless it comes within a specific exemption. National Ass’n of Retired Fed. Employees v. Horner, 879 F.2d 873, 879 (D.C.Cir.1989) (emphasis in original). Indeed, Public Citizen’s main reason for seeking this information is to “review whether the FDA is adequately safeguarding the health of people who participate in drug trials”; the information sought, in other words, would reveal “what the[ ] government is up to.” DOJ v. Reporters Comm. for Freedom of Press, 489 U.S. 749, 773, 109 S.Ct. 1468, 103 L.Ed.2d 774 (1989). It is not open to Public Citizen, however, to bolster the case for disclosure by claiming an additional public benefit in that, if the information is disclosed, then other drug companies will not conduct risky clinical trials of the drugs that Schering has abandoned. That is not related to “what the[ ] government is up to” and the Court has clearly stated that “whether disclosure of a ... document ... is warranted must turn on the nature of the requested document and its relationship to the basic purpose of the Freedom of Information Act to open agency action to the light of public scrutiny ... rather than on the particular purpose for which the document is being requested.” Id. at 772, 109 S.Ct. 1468. In other words, the public interest side of the balance is not a function of the identity of the requester, see id. at 771, 109 S.Ct. 1468, or of any potential negative consequences disclosure may have for the public, Washington Post Co. v. HHS, 865 F.2d 320, 327-28 (D.C.Cir.1989), nor likewise of any collateral benefits of disclosure.
In litigation seeking the release of information under the FOIA, “the agency has the burden of showing that requested information comes within a FOIA exemption.” Niagra Mohawk Power Corp. v. DOE, 169 F.3d 16, 18 (D.C.Cir.1999). Even when the requester files a motion for summary judgment, the Government “ultimately [has] the onus of proving that the [documents] are exempt from disclosure.” National Ass’n of Gov’t Employees v. Campbell, 593 F.2d 1023, 1027 (D.C.Cir.1978). The burden upon the requester is merely “to establish the absence of materi*905al factual issues before a summary disposition of the case could permissibly occur.” Id. Accordingly, in order to obtain a summary judgment Public Citizen need not demonstrate that Schering would suffer no competitive harm from the release of this information; rather, its task is to show that there is no dispute about an issue of fact material to the FDA’s burden of demonstrating that Schering would suffer substantial competitive harm from the disclosure of its INDs. See National Parks I, 498 F.2d at 770.
1. IND Nos. 35757, 34465, 31911, and 30647
For the reasons stated in the opinion of the district court, 997 F.Supp. at 63-64, we agree with the FDA and Schering that under Exemption 4 the agency may withhold information in the four INDs listed above. Release of that information would cause substantial harm to Schering’s competitive position.
With respect to the first three INDs, Public Citizen contends that releasing health and safety information would only “save Schering’s competitors the time Schering spent developing and testing a dangerous drug, and thus save human trial participants from being exposed to a dangerous drug.” According to Public Citizen, that “cannot be considered the type of ‘competitive harm’ justifying withholding of the documents under Exemption 4.”
Having already rejected Public Citizen’s argument that any collateral benefit from the disclosure of information — that is, any benefit beyond learning “what the[ ] government is up to” — must be weighed against the competitive harm that would result from disclosure, we do not consider Public Citizen’s assertion that disclosure would in fact prevent the exposure of human beings to a health risk. In any event, as both the FDA and Schering point out, were a competitor to submit an IND involving a risk known to the FDA because of its experiences with Schering’s INDs, the agency could and presumably would refuse to permit that company to begin clinical testing.
We turn therefore to Schering’s evidence of competitive harm from disclosure of these three INDs, all of which relate to the same antifungal drug. According to the. affidavit of its Dr. George H. Miller, the Company “has just commenced clinical testing on a successor [drug] which was designed based on information learned during development of [the drugs described in those INDs].” Further, Dr. Miller states that “Schering’s basic research revealed that the particular type of fungal infection for which this product was designed was not one that was relatively well-controlled by existing products.” He also states that “[t]he development and marketing of new antifungal products is ... being actively engaged in by a number of other drug companies,” which could make use of the information in the INDs in order to eliminate much of the time and effort that would otherwise be required to bring to market a product competitive with the product for which Schering filed its most recent IND. This is clearly the type of competitive harm envisioned in Exemption 4, as our case law makes clear. See, e.g., National Parks & Conservation Ass’n v. Kleppe (“National Parks II”), 547 F.2d 673, 684 (D.C.Cir.1976) (“Disclosure would provide competitors with valuable insights into the operational strengths and weaknesses of a [company], while [its competitors] could continue in the customary manner of ‘playing their cards close to their chest’ ”); cf. Webb v. HHS, 696 F.2d 101, 103 (D.C.Cir.1982) (“If a manufacturer’s competitor could obtain ‘all the data in the manufacturer’s NDA, it could utilize them in its own NDA without incurring the time, labor, risk, and expense involved in developing them independently”).
The fourth IND listed above concerned a drug “designed to suppress allergic inflammations and subsequent symptoms of asthma.” Public Citizen concedes that Schering is now testing compounds related to the abandoned drug. Nonetheless, Public Citizen complains that the Company does not “explain with any specificity how the pre-clinical and clinical studies on the *906old compound would lead its competitors to the new compounds that Schering has subsequently identified.”
In the affidavit Schering filed to support withholding the documents in this IND, Dr. Francis Cuss recounts that the Company initially believed the drug was a “leu-kotrine inhibitor,” but that its “scientists observed certain unanticipated effects during toxicity and clinical testing .... suggesting] that the drug may have achieved its anti-inflammatory effects through a [different] mechanism.” Therefore, states the affiant, the “toxicity and clinical data together could direct a competitor of Schering .... to pursue the the same avenues of research and development” that Schering has pursued since abandoning this IND. We think this explanation sufficiently specific to support Schering’s argument that disclosure of information in this IND would cause it substantial competitive harm.
Accordingly, we reverse that portion of the district court’s order requiring the agency to release the documents in these four INDs. See Critical Mass, 975 F.2d at 880.
2. IND No. 18113
We turn now to the documents in the fifth IND, which involved “one of four isomers making up a prescription medicine currently marketed by Schering and indicated for use in controlling blood pressure in cases of severe hypertension.” We find that Schering’s affidavit professing the extent of competitive injury it would suffer from disclosure of the information in this IND is not sufficient to support its motion for summary judgment; indeed, it fails to raise a dispute as to any material issue of fact. Summary judgment for Public Citizen is therefore indicated.
The affidavit of Schering’s Dr. Ronald J. Garutti contains only conclusory assertions that disclosure would cause substantial competitive harm. For example, the affiant states that disclosure “would reveal substantial basic research” as well as “disease models ... that have been developed by Schering at a great expense,” and that “[t]oxicology data ... have significant value beyond the compound under investigation .... [and would be applicable] to any drug product any of whose metabolites were identical or similar to those of IND 18113_ [and] other drugs [of] a similar chemical type.” Dr. Garutti attests that the clinical protocols also “have applicability beyond the specific drug being tested” and that disclosure “would have substantial commercial value to any company attempting to develop cardiovascular therapies generally.” The arguments in Schering’s brief are even more general: disclosure would reveal its “assessment of regulatory requirements and its experience with FDA in this area, as well as [its] judgment as to what requirements will be necessary in order to establish the drug’s safety and effectiveness.”
Although a party opposing a motion for summary judgment is entitled to every favorable inference that may fairly be drawn from its affidavits, see Greenberg v. FDA, 803 F.2d 1213, 1216 (D.C.Cir.1986), such “[c]onclusory and generalized allegations of substantial competitive harm ... cannot support an agency’s decision to withhold requested documents.” Public Citizen Health Research Group v. FDA, 704 F.2d 1280, 1291 (D.C.Cir.1983). Accordingly, we hold that the agency may not withhold the disputed documents in IND No. 18113 under Exemption 4. We therefore affirm that portion of the district court’s order requiring the agency to release them to Public Citizen, albeit for a different reason.
C. Segregability
In view of our holding that the agency may, under Exemption 4, withhold information in four of the INDs, we turn to Public Citizen’s alternative request that we remand the case for the district court to determine whether any non-exempt portions of the documents that the agency may withhold can be segregated and disclosed. Public Citizen contends that the *907district court did not have occasion to make this determination because it required disclosure of all the records. Schering responds that the district court did not do so because Public Citizen never asked for, and therefore waived, such relief, and that segregation would in any event be “unreasonable” in this case.
From the record we see that Public Citizen did raise this issue before the district court in its Reply in Support of its Cross-Motion for Summary Judgment. In any event, on remand it would be incumbent upon the district court on its own initiative to address the issue of segregability. See Trans-Pacific Policing Agreement v. United States Customs Serv., 177 F.3d 1022, 1028 (D.C.Cir.1999). One should normally presume that a request for information under the FOIA is a request for all or any, not for all or none, of the information described. Cf. National Mining Ass’n v. Babbitt, 172 F.3d 906, 910 (D.C.Cir.1999) (factual presumption is reasonable when “the circumstances giving rise to the presumption ... make it more likely than not that the presumed fact exists”).
In view of the district court’s disposition of this case, of course, it had no need to address the issue of segregability the first time around and we do not fault it for passing over the issue then. We have now held, however, that information in four of the five INDs at issue may be withheld. Because “[t]he focus in the FOIA is information, not documents, and an agency cannot justify withholding an entire document simply by showing that it contains some exempt material,” we remand this case for the district court to determine whether the documents the agency has withheld contain information that can be segregated and disclosed. Schiller v. NLRB, 964 F.2d 1205, 1209-10 (D.C.Cir.1992). In so doing, we express no opinion upon Schering’s claim that segregation is impracticable in this case.
III. Summary and Conclusion
For the foregoing reasons, we hold first that § 355(l) applies only to information submitted in an NDA. In addition we hold that the FDA has not met its burden under Exemption 4 with respect to, and therefore must disclose, the information contained in IND No. 18113; and that the agency has met its burden under Exemption 4 with respect to, and therefore need not disclose, confidential information contained in IND Nos. 35757, 34465, 31911, and 30647. As to the latter four INDs, we remand the case for the district court to determine in the first instance whether there is any nonconfidential information that can be segregated and disclosed.
So ordered.
Our concurring colleague is of the opinion that Public Citizen has failed to create a genuine issue of material fact as to whether disclosure is necessary to safeguard participants in clinical trials, and therefore that it has not done enough to prevent summary judgment from being entered against it, even if its view of the law were correct. See Concur. at 907 & n.1. The record, however, makes clear that Public Citizen has more than met its burden of raising a dispute over this fact. The affidavit it submitted to the district court states:
Defendants’ arguments of substantial competitive harm are disturbing from a public health standpoint because the data we seek involve experimental drugs that were determined to pose such serious health or safety risks that clinical testing of the drug was stopped. ... [B]ecause the safety and effectiveness data for this experimental drug is being withheld, we cannot determine whether the FDA adequately protected human subjects in these clinical trials. Defendants will not be competitively harmed from the release of [this information] because tests that reveal the hazards of a drug are simply not the type of studies that competitors would want to copy. On the other hand, the public will benefit significantly from their release. Indeed, if these studies are kept secret, other drug companies may unknowingly conduct similarly hazardous studies, potentially placing many patients needlessly at risk.
Similarly, Public Citizen's affiant states: “disclosure ... serves the public interest in two independent ways. First, it allows the public to scrutinize FDA's decisions concerning human testing of investigational drugs.... Second, disclosure of safety and effectiveness data decreases the likelihood that other drug companies will replicate potentially hazardous human testing.’’
That the FDA claims it has another, more direct, way to prevent exposure of human *904beings to this risk, see Op. at 905, merely joins the dispute on the factual question; it does not resolve it. See Niagra Mohawk Power Corp. v. DOE, 169 F.3d 16, 18-19 (D.C.Cir.1999).